<DOC>
	<DOCNO>NCT00746798</DOCNO>
	<brief_summary>The purpose study determine ChimeriVax West Nile vaccine safe effective prevent West Nile disease adult 50 year age .</brief_summary>
	<brief_title>Safety Immunogenicity Study ChimeriVax West Nile Vaccine Healthy Adults</brief_title>
	<detailed_description>Currently , method prevention West Nile infection control mosquito vector associate avoidance mosquito bite , proven largely ineffective . Developing safe , effective vaccine make widely available enhance prospect prevention control disease . In addition , natural infection YF virus WN virus severe elderly . Therefore , study among healthy old subject well control chronic disease provide data determine ChimeriVax-WN02 vaccine dose immunogenic well tolerate .</detailed_description>
	<mesh_term>West Nile Fever</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Written inform consent Medically stable , ambulatory male female ≥ 50 year age . Attend schedule visit comply study procedure . Negative serum pregnancy test Screening , negative urine pregnancy test Day 0 . Known suspected congenital acquire immunodeficiency , immunosuppressive therapy anticancer chemotherapy radiation therapy within precede 6 month , longterm ( least 2 week within previous 3 month ) systemic corticosteroid therapy ( dose least 10 mg prednisone equivalent ) , depot preparation within previous 3 month . Topical steroid allow . Administration immunoglobulins and/or blood product within 3 month enrollment plan administration treatment period study . Presence acute chronic illness associate oral temperature &gt; 38.0 °C require hospitalization time enrollment . Any following serological finding Screening : positive Hepatitis B surface antigen ( HBsAg ) , positive Hepatitis C ( antiHCV ) , positive human immunodeficiency virus ( HIV ) . Personal family history thymic pathology ( e.g. , thymoma ) , thymectomy , myasthenia . History significant allergic reaction vaccine component Asplenia , functional asplenia , condition result absence removal spleen . Active potentially progressive neurologic disease injury include limited : Parkinson 's , Guillain Barré , epilepsy , seizure ( except febrile seizure age 2 ) , cerebrovascular accident , head trauma require hospitalization within precede 3 year , neurologic condition think impact integrity blood brain barrier . Clinically significant abnormal ECG finding Screening Impaired hepatic function , and/or clinically significant unexplained elevation alanine aminotransferase ( ALT , SGPT ) , aspartate aminotransferase ( AST , SGOT ) &gt; 3X upper limit normal . Impaired renal function , show limited , serum creatinine &gt; 2.0 mg/dL . Impaired hematopoietic function and/or clinically significant hematological laboratory abnormality . A history alcohol drug abuse within 12 month prior study entry . Pregnant lactate woman woman childbearing potential use acceptable method contraception least 28 day prior enrollment . Post menopausal woman consider childbearing potential 1 year last menstrual period . Behavioral , cognitive , psychiatric disease , opinion Investigator affect ability subject understand scope study and/or unlikely able compliant study procedures visit . Any condition , Investigator 's judgment , might result increase risk subject , would affect subject 's participation study . Participation another clinical trial investigate vaccine , drug medical procedure 30 day precede informed consent . Any vaccine administer within 30 day prior study vaccination . Note : Influenza vaccine administer 1 week precede study vaccination . Planned participation another clinical trial present trial period . Planned receipt vaccine 4 week follow trial vaccination . Research site personnel family member enrol subject trial .</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>West Nile Fever</keyword>
	<keyword>ChimeriVax</keyword>
	<keyword>West Nile Virus Vaccine</keyword>
</DOC>